Algeria vs Central African Republic: Protecting minority investors: Ease of shareholder suits index (0-10)
Algeria
50
in 2019
Central African Republic
50
in 2019
Algeria rank
128th
Central African Republic rank
128th
Protecting minority investors: Ease of shareholder suits index (0-10) over time
- Algeria
- Central African Republic
How they compare
Algeria currently reports 50 against 50 in Central African Republic, a difference of 0.
The two have swapped places 1 time across 7 shared years of data; in 2013 it was Algeria ahead.
Algeria ranks 128th and Central African Republic ranks 128th of 191 countries.
Algeria has averaged higher in every one of the 1 decades both report.
Frequently asked questions
- Which has higher protecting minority investors: ease of shareholder suits index (0-10), Algeria or Central African Republic?
- Algeria, at 50 against 50 in Central African Republic as of 2019.
- What is the difference in protecting minority investors: ease of shareholder suits index (0-10) between Algeria and Central African Republic?
- 0, with Algeria ahead.
- How many years of comparable data are there for Algeria and Central African Republic?
- 7 years are reported by both, from 2013 to 2019.
- How do Algeria and Central African Republic rank globally for protecting minority investors: ease of shareholder suits index (0-10)?
- Algeria ranks 128th and Central African Republic ranks 128th of 191 countries.
- Where does this data come from?
- The World Bank, published as Protecting minority investors: Ease of shareholder suits index (0-10) (DB15-20 methodology) - Score. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The score for ease of shareholder suits index benchmarks economies with respect to the regulatory best practice on the indicator. The score is indicated on a scale from 0 to 100, where 0 represents the worst regulatory performance and 100 the best regulatory performance, and is computed based on the methodology in the DB15-20 studies.